CIN-103 is under clinical development by Cinphloro Pharma and currently in Phase II for Irritable Bowel Syndrome. According to GlobalData, Phase II drugs for Irritable Bowel Syndrome have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CIN-103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CIN-103 overview
CIN-103 is under development for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). It is a phenol derivative. The drug candidate is a new chemical entity. It is a modified pulsatile-release formulation of phloroglucinol. It is administered through oral route in the form of capsules.
Cinphloro Pharma overview
Cinphloro Pharma is a biotechnology company that specializes in developing long-term treatment for irritable bowel syndrome with predominant diarrhea. The company is headquartered in Cincinnati, Ohio, the US.
For a complete picture of CIN-103’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
